Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)

Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3) - Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003402

Enrollment

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resectable pancreatic cancer

Interventions

Neoadjuvant chemotherapy with gemcitabine and S1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) invasive ductal carcinoma of the pancreas 2) no distant metastasis 3) R0/1 resectable 4) all adult who anticipate to undergo pancreatectomy 5) no prior therapy 6) written informed consent

Exclusion criteria

Exclusion criteria: 1) pulmonary fibrosis or interstitial pneumonitis 2) tumor other than ductal carcinoma 3) distant metastasis 4) R2 resection 5) prior anti-cnacer therapy 6) pregnancy 7) under 18 years old

Design outcomes

Secondary

Measure	Time frame
Adverse effect, pathological effect, recurrence free survival, overall survival, patterns of recurrence, reduction rate and normalization rate for tumor marker	—

Primary

Measure	Time frame
True R0 resection rate; The rate of R0 resection with the normalized post-operative tumor markers	—

Countries

Japan

Contacts

Public ContactFuyuhiko Motoi

Miyagi HBPCOG Coordinating office

fmotoi@surg1.med.tohoku.ac.jp022-717-7205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026